BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, August 3, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

In the clinic for Dec. 22, 2021

Dec. 22, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aldeyra, Allakos, Alnylam, Clearside, Eiger, Eli Lilly, Medigene, Novaliq, Novaremed, Novavax, Pfizer, Phasebio, Repare, /Rigel, Statera, Telix, TFF, Urogen, Urovant, Valneva, Vifor.
Read More
Man uses smartphone to take picture of BD Veritor At-Home COVID-19 test

BD closes acquisition of Scanwell as demand for Veritor at-home test surges

Dec. 21, 2021
By Annette Boyle
Becton, Dickinson and Co. (BD) completed its acquisition of Scanwell Health Inc., its partner in development of the smartphone-enabled BD Veritor At-Home COVID-19 Test, just in time for increased demand driven by the Omicron surge in the U.S. and plans to make the tests available for free by the federal government as well as several states and large municipalities. Currently, most of the tests distributed by governments are made by Abbott Laboratories, which received emergency use authorization (EUA) for its at-home test in March 2021.
Read More
Digital illustration of U.S., coronavirus

US promises surge in at-home COVID-19 tests, but can companies deliver?

Dec. 21, 2021
By Mark McCarty
As the Omicron variant of COVID-19 sweeps across the globe, the Biden administration has announced a program to purchase 500 million rapid antigen tests to help slow the pandemic. The news comes at an especially critical time, given the increased transmissibility of the Omicron variant, but the promised volume is unlikely to be achieved by the first day of January 2022.
Read More
British pound symbol

Bond Digital Health to expand digital lateral flow tool beyond COVID-19

Dec. 21, 2021
By Catherine Longworth
Bond Digital Health Ltd. landed £1 million (US$1.3 million) from investors to expand development of its Transform data management system for lateral flow diagnostic tests. The technology connects to an app that captures data from lateral flow assays in self-testing settings. The results are then shared to a dashboard that can be monitored by the platform admin. The new investment included equity funding from the Development Bank of Wales and high-net-worth investment service Wealth Club. In addition to the current round, Bond is aiming to raise a further £500,000 by January.
Read More

Other news to note for Dec. 21, 2021

Dec. 21, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Access Strategy Partners, Aurora Spine, Avero Diagnostics, Biosig Technologies, Emulate, Heraeus Holding, Jolly Good, Medina Healthcare, Nanovibronix, Norwood Medical, Precision Manufacturing, Progenity, Steribite, Thermo Fisher Scientific.
Read More

In the clinic for Dec. 21, 2021

Dec. 21, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Fast Biomedical, Ondine.
Read More

COVID-19 holiday wrapping: Data from Aridis and Moderna show strength against Omicron

Dec. 21, 2021
By Lee Landenberger
Aridis Pharmaceuticals Inc. is one of two companies posting COVID-19 data just days before Christmas. Its fully human monoclonal antibody cocktail, AR-701, was shown to be broadly reactive against COVID-19 variants, including Omicron, in preclinical research. Moderna Inc. also posted new data that showed preliminary neutralizing data against Omicron following 50-mg doses of its vaccine, which is currently authorized, and 100-mg dose boosters, which increased neutralizing antibody levels 83-fold from the pre-boost levels.
Read More

Providence and Everest’s vaccine is first mRNA in WHO’s Solidarity Trial Vaccines study

Dec. 21, 2021
By David Ho
Everest Medicines Ltd. and Providence Therapeutics Holdings Inc.’s COVID-19 vaccine was cleared for inclusion in the World Health Organization’s (WHO) Solidarity Trial Vaccines clinical trial.
Read More

Regulatory actions for Dec. 21, 2021

Dec. 21, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advicenne, Alnylam, Argenx, Astrazeneca, Bluebird, Cara, Coherus, Edenbridge, Editas, Everest, GBT, Intra-Cellular, Lannett, Lysogene, Moderna, Novavax, Polarityte, Poseida, Providence, Sorrento, Takeda, Telix, Zogenix.
Read More

In the clinic for Dec. 20, 2021

Dec. 20, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Affera, Cytosorbents, Magforce, Vesper, Xeltis, Zynex.
Read More
Previous 1 2 … 151 152 153 154 155 156 157 158 159 … 553 554 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 3, 2026.
  • Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors

    BioWorld Science
    Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
  • Silhouette illustration of DNA gene editing

    Death in Chinese gene-editing trial exposes ethical fault lines

    BioWorld
    The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
  • Mitochondria

    Seed funding at Adjuvia to treat mitochondrial dysfunction

    BioWorld Science
    Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
  • Skin through magnifier

    Replimune’s RP-1 for melanoma wins over FDA adcom

    BioWorld
    Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing